Merck
CN
  • Supplementation of pyruvate prevents palmitate-induced impairment of glucose uptake in C2 myotubes.

Supplementation of pyruvate prevents palmitate-induced impairment of glucose uptake in C2 myotubes.

Molecular and cellular endocrinology (2011-08-02)
Jong Gab Jung, Sung-E Choi, Yoon-Jung Hwang, Sang-A Lee, Eun Kyoung Kim, Min-Seok Lee, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Yup Kang, Kwan-Woo Lee
ABSTRACT

Elevated fatty acid levels have been thought to contribute to insulin resistance. Repression of the glucose transporter 4 (GLUT4) gene as well as impaired GLUT4 translocation may be a mediator for fatty acid-induced insulin resistance. This study was initiated to determine whether palmitate treatment repressed GLUT4 expression, whether glucose/fatty acid metabolism influenced palmitate-induced GLUT4 gene repression (PIGR), and whether attempts to prevent PIGR restored palmitate-induced impairment of glucose uptake (PIIGU) in C2 myotubes. Not only stimulators of fatty acid oxidation, such as bezafibrate, AICAR, and TOFA, but also TCA cycle substrates, such as pyruvate, leucine/glutamine, and α-ketoisocaproate/monomethyl succinate, significantly prevented PIGR. In particular, supplementing with pyruvate through methyl pyruvate resulted in nearly complete prevention of PIIGU, whereas palmitate treatment reduced the intracellular pyruvate level. These results suggest that pyruvate depletion plays a critical role in PIGR and PIIGU; thus, pyruvate supplementation may help prevent obesity-induced insulin resistance in muscle cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyl pyruvate, 90%, technical grade